VIENNA Why closing knowledge gaps matters for patients, healthcare and innovation. (BUSINESS WIRE)--Between 27 and 36 million1 people in Europe are living with a rare disease, yet only around six percent currently have access to an approved treatment2. Progress in diagnosis and treatment is often slowed by knowledge gaps, including the lack of clear, reliable, and patient-friendly information needed to support informed decision-making. Drawing on 30 years of experience in researching and developing therapies for rare diseases, AOP Health underscores the importance of collaboration across the healthcare community. On Rare Disease Day 2026, the company joins healthcare professionals, researchers and patient representatives in highlighting the need for closer cooperation to generate, share and better use scarce data to improve care for people living with rare diseases. “Working in rare diseases since 1996 has shown us that innovation is never a solo effort,” emphasized Melissa Felln ... Read more »

As an optical imagery provider, Axelspace has entered into a contract for the acquisition of image data

(BUSINESS WIRE) -- Axelspace Corporation (“Axelspace”), a leading developer and operator of microsatellites dedicated to realizing its vision of “Space within Your Reach,” announced that, for the purpose of carrying out the Ministry of Defense’s satellite constellation project, it has entered into a contract with Tri-Sat Constellation Co., Ltd. and Mitsui Bussan Aerospace Co., Ltd. for acquisition of optical imagery data. Tri-Sat Constellation Co., Ltd. is a special purpose company (SPC) established by Mitsubishi Electric Corporation, SKY Perfect JSAT Corporation, and Mitsui & Co., Ltd.

The Ministry of Defense’s satellite constellation project was awarded to a consortium comprising Mitsubishi Electric Corporation, SKY Perfect JSAT Corporation, Mitsui & Co., Ltd., Synspective Inc., Institute for Q-shu Pioneers of Space, Inc., Mitsui Bussan Aerospace Co., Ltd., ... Read more »

LAS VEGAS -
Fourth Quarter and Full Year 2025 Financial Highlights Include:

Remaining Performance Obligations (RPO) of $652.9 million, up 11.1% from the prior year

Adjusted Calculated Billings, full year 2025, up 4.2% from the prior year

Adjusted Annualized Recurring Revenue (ARR) up 3.1% from the prior year



(BUSINESS WIRE)--Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the 2025 fourth quarter and fiscal year ended December 31, 2025.

“Our fourth quarter results reflect solid execution and continued accelerating sales growth, adjusted for the Oracle PeopleSoft support and services wind down. We grew our core Rimini Support™ subscription billings and launched our next generation Agentic AI ERP solutions that can be easily ... Read more »

OSAKA, Japan & CAMBRIDGE, Mass. - Friday, 20. February 2026 AETOSWire

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor (TNF) antagonists, found nearly half (47.3%) of randomized patients achieved primary endpoint of clinical remission at 54 weeks
Vedolizumab’s safety profile was generally consistent with its known safety profile in adults
Results were presented at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO)


(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can offer the possibility of clinical remission for patients ages 2 and older with moderately to severely active ulcerative colitis (UC), a chronic inflammatory disease of the gastrointestinal tract and one of the ... Read more »